Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature.
Short-term cyclophosphamide pulse therapy was administered to five patients with idiopathic inflammatory myopathies (IIM) which were refractory to corticosteroids and, in two cases, to other aggressive therapies. Both disease remission and a reduction in corticosteroid dosage were obtained in four patients. Three of them have been in remission over since, taking only minimal doses of steroids during the subsequent two years. In the fourth patient a less intensive, maintenance pulse therapy could not be continued due to unacceptable side effects. On the basis of these results and of data from the literature, herein reviewed, cyclophosphamide pulse therapy may be recommended for adult patients with IIM who do not respond to or who do not tolerate conventional corticosteroid treatment, as well as when a steroid-sparing effect is desired.
De Vita
S
S
4th Department of Medicine, Ospedale Civile S. Maria della Misericordia, Udine, Italy.
Fossaluzza
V
V
D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D009119:Muscle Contraction; D009220:Myositis / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use
D003520:Cyclophosphamide; D003402:Creatine Kinase; D011241:Prednisone